Fujifilm Announces Financial Results for the First Half Ended September 30, 2026

First Half Results for the Fiscal Year Ending March 31, 2027

• Revenue was JPY1,711.5 billion and increased 8.8% year-over-year.
• Operating income was JPY141.2 billion and decreased 10.9% year-over-year.
• Net income attributable to FUJIFILM Holdings was JPY105.2 billion and decreased 12.5% year-over-year.

Outlook for Fiscal Year Ending March 31, 2027

• For the fiscal year ending March 2027, the company projects record-high revenue of JPY3.59 trillion, reflecting strong sales of Medical Systems and Semiconductor Materials.
• Operating income is expected to reach JPY365.0 billion, in line with the previous forecast, as increased profits in the Electronic Materials segment are expected to be offset by factors including a decline in gross profit resulting from lower revenue in the Business Innovation segment.
• Net income attributable to FUJIFILM Holdings is forecasted at JPY280.0 billion.

In the second quarter, the three months ended September 30, 2026, Fujifilm achieved record-high revenue, operating income and net income attributable to FUJIFILM Holdings supported by strong sales of endoscopes in Healthcare segment, semiconductor materials and data tapes in Electronics segment, and instax^™ products in Imaging segment, while continuing to improve profitability in the Bio CDMO business and strengthening the operational foundation of the Business Innovation segment.

“We continue to capture robust demand across our growth businesses and deliver solid growth across the Company. As we enter the final six months of our current medium-term management plan, VISION2030, we will remain firmly focused on delivering results, while executing the necessary reforms and establishing a clear path toward our next medium-term management plan,” says Teiichi Goto, president and chief executive officer, representative director, FUJIFILM Holdings Corporation.

Second-quarter financial highlights from July to September by business segments

Healthcare

• Revenue increased by 9.8% year-over-year to JPY297.3 billion, while operating income declined 17.3% year-over-year to JPY16.0 billion, primarily due to upfront costs associated with the start-up of new large-scale Bio CDMO facilities in the United States, the impact of unplanned shutdowns in response to regulatory inspections, and higher raw material costs due to surging silver prices.
• In the Medical Systems business, revenue increased, driven by significant performance in endoscope in the United States, continued strong growth in Europe and Japan, as well as in India, Southeast Asia and other markets, and higher sales of MRI systems and IVD products.
• In the Bio CDMO business, revenue increased, driven by the ramp-up of new large-scale facilities.
• In the LS Solutions business, revenue increased, driven by expanded use of cell culture media among major pharmaceutical companies.

Electronics

• Revenue increased by 23.0% year-over-year to JPY132.0 billion, and operating income rose by 66.6% year-over-year to JPY32.4 billion.
• In the Electronic Materials business, revenue increased, driven by strong sales of advanced-node materials, including those used in generative AI applications, such as the world’s leading CMP slurries for copper interconnects, NTI developers and liquid polyimides.
• In the Advanced Functional Materials business, revenue increased, supported by higher sales of data tapes to major IT companies, among other factors.

Business Innovation

• Revenue decreased by 1.7% year-over-year to JPY293.5 billion, and operating income declined by JPY14.9 billion year-over-year to JPY0.9 billion.
• In the Business Solutions business, revenue decreased, primarily due to the absence of large-scale projects for local governments recorded in the previous fiscal year and lower revenue from related services as PC and server projects in Japan were postponed to the second half of the fiscal year due to semiconductor supply constraints.
• In the Office Solutions business, revenue declined due to lower exports to Europe and North America.
• In the Graphic Communications business, revenue increased, supported by higher sales of production printer Revoria Press series in new markets.

Imaging

• Revenue increased by 11.0% year-over-year to JPY162.3 billion, and operating income rose by 29.6% year-over-year to JPY50.1 billion.
• In the Consumer Imaging business, revenue increased due to strong sales of instax^™ products, supported by robust demand for mid- to high-end models such as the instax mini Evo^™ and instax WIDE 400^™, coupled with strong sales of the new entry-level instax mini 13^™.
• In the Professional Imaging business, revenue decreased due to the impact of strong sales of new products in the same period of the previous fiscal year.

For more details, please visit the Investor Relations section of Fujifilm website.